SEQUENCE LISTING

<110> Smith, Ernest S.
Zauderer, Maurice

<120> Use of Semaphorin-4D Binding Molecules to Promote Neurogenesis Following Stroke

<130> 1843.072PC01/EJH/BNC

<140> To be assigned
<141> Herewith

<150> US 13/842,523
<151> 2012-03-15

<150> US 61/646,119
<151> 2012-05-11

<160> 18

<170> PatentIn version 3.5

<210> 1
<211> 118
<212> PRT
<213> Artificial Sequence

<220>
<223> MAb 67 VH

<400> 1

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Ser Asp Tyr
20 25 30

Tyr Met His Trp Val Lys Gln Ser Pro Glu Asn Ser Leu Glu Trp Ile
35 40 45

Gly Gln Ile Asn Pro Thr Thr Gly Gly Ala Ser Tyr Asn Gln Lys Phe
50 55 60

Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met Gln Leu Lys Ser Leu Thr Ser Glu Glu Ser Ala Val Tyr Tyr Cys
85 90 95

Thr Arg Tyr Tyr Tyr Gly Arg His Phe Asp Val Trp Gly Gln Gly Thr
100 105 110

Thr Val Thr Val Ser Ser
115

<210> 2
<211> 111

<212> PRT
<213> Artificial Sequence

<220>
<223> MAb 67 VK

<400> 2

```
Asp Ile Val Met Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
1               5                  10                  15

Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp
            20                  25                  30

Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
        35                  40                  45

Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala
    50                  55                  60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His
65                  70                  75                  80

Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Asn
                85                  90                  95

Glu Asp Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
            100                 105                 110
```

<210> 3
<211> 118
<212> PRT
<213> Artificial Sequence

<220>
<223> MAb 2503 H2160

<400> 3

```
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1               5                  10                  15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Ser Asp Tyr
            20                  25                  30

Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
        35                  40                  45

Gly Gln Ile Asn Pro Thr Thr Gly Gly Ala Ser Tyr Asn Gln Lys Phe
    50                  55                  60

Lys Gly Lys Ala Thr Ile Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95
```

Ala Arg Tyr Tyr Tyr Gly Arg His Phe Asp Val Trp Gly Gln Gly Thr
100 105 110

Thr Val Thr Val Ser Ser
115

<210> 4
<211> 111
<212> PRT
<213> Artificial Sequence

<220>
<223> MAb 2503 L553

<400> 4

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15

Glu Arg Ala Thr Ile Asn Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp
20 25 30

Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
35 40 45

Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Val Pro Asp
50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
65 70 75 80

Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Ser Asn
85 90 95

Glu Asp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 5
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Polypeptide anti-CD100 VH CDR1

<400> 5

Gly Tyr Ser Phe Ser Asp Tyr Tyr Met His
1 5 10

<210> 6
<211> 17
<212> PRT
<213> Artificial Sequence

<220>

<223> Polypeptide anti-CD100 VH CDR2

<400> 6

Gln Ile Asn Pro Thr Thr Gly Gly Ala Ser Tyr Asn Gln Lys Phe Lys
1 5 10 15

Gly

<210> 7
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Polypeptide anti-CD100 VH CDR3

<400> 7

Tyr Tyr Tyr Gly Arg His Phe Asp Val
1 5

<210> 8
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Polypeptide anti-CD100 VL CDR1

<400> 8

Lys Ala Ser Gln Ser Val Asp Tyr Asp Gly Asp Ser Tyr Met Asn
1 5 10 15

<210> 9
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Polypeptide anti-CD100 VL CDR2

<400> 9

Ala Ala Ser Asn Leu Glu Ser
1 5

<210> 10
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Polypeptide anti-CD100 VL CDR3

<400> 10

Gln Gln Ser Asn Glu Asp Pro Tyr Thr
1 5

<210> 11
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> nestin forward

<400> 11
cactagaaag caggaaccag 20

<210> 12
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> nestin reverse

<400> 12
agatggttca caatcctctg 20

<210> 13
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Sox2 forward

<400> 13
ttgggagggg tgcaaaaaga 20

<210> 14
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Sox2 reverse

<400> 14
cctgcgaagc gcctaacgta 20

<210> 15
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> PLP forward

<400> 15
tgagcgcaac ggtaacagg 19

<210> 16
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> PLP reverse

<400> 16
gggagaacac catacattct gg 22

<210> 17
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Beta-actin forward

<400> 17
gctcgtcgtc gacaagggct c 21

<210> 18
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Beta-actin reverse

<400> 18
caaacatgat ctgggtcatc ttctc 25